ÂÜÀòÂÒÂ×

Cyril B. DOUSSON is an accomplished leader in the pharmaceutical and biotechnology sectors, currently serving as CEO of Ai-biopharma since February 2018, with a focus on antiviral therapies and functional cures for HBV and CoV. In addition to this role, Cyril B. DOUSSON is a Board Member of BCI PHARMA and Ecole Nationale Supérieure de Chimie de Montpellier, as well as a Board Member of Eurobiomed. Prior experience includes leading medicinal chemistry at Merck and Idenix Pharmaceuticals, specializing in antiviral and oncology research. Academic credentials include a Ph.D. in Organic Chemistry from the University of Liverpool and advanced degrees in bioconversion and biology from Aix-Marseille University and the University of Montpellier, respectively.